课题基金 / 基金详情

COVID-19 Variant Supplement - Improving Outcomes in Individuals with COVID-19 with Renin-Angiotensin System Inhibition: The COVID-RASi Trial

COVID-19 Variant Supplement - Improving Outcomes in Individuals with COVID-19 with Renin-Angiotensin System Inhibition: The COVID-RASi Trial
COVID-19 变异补充剂 - 通过肾素-血管紧张素系统抑制改善 COVID-19 患者的治疗结果：COVID-RASi 试验
批准号：
443205
负责人：
Liu Peter P
金额：
$3.64万
依托单位：
Ottawa Heart Institute Research Corporation (Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
已结题
起止时间：
2021-02-01 至 2022-02-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=443205&lang=en
关键词：
Ace Inhibitors Angiotensin Receptor Blockers Cardiovascular Disease Covid-19 Elderly Icu Admission Randomized Trial Renin-Angiotensin System Inhibitors

项目摘要

项目成果

Liu Peter P的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Cardiovascular disease is not only the #1 killer chronically, but is also the #1 killer in COVID-19. Elderly patients with previous heart attack or stroke, or hypertension or diabetes, have high risk of getting infected. Surprisingly they also suffer 3 t
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The COVID-R3ICSAB Study: COVID-19 Wide Impact: Research on the Risk and Resilience In Special Communities of Chinese, South Asian and Black Populations
COVID-19 Vaccine-Induced Inflammatory Heart Disease Prevalence Registry and Cohort Study (COVID-VIHPR)
Improving Outcomes in Individuals with COVID-19 with Renin-Angiotensin System Inhibition: The COVID-RASi Trial
Developing Novel Therapeutic Targets for Heart Failure
海外基金